WORCESTER, Mass., Dec. 14, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The results were presented at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org). The trial is being conducted by COL George Peoples, MD, a collaborator of Antigen Express working at the Brooke Army Medical Center.
